What is a G-quadruplex?
A G-quadruplex (G4) is a non-B-form DNA (or RNA) secondary structure formed by guanine-rich sequences. Four guanines arrange in a planar tetrad through Hoogsteen hydrogen bonding: each guanine acts simultaneously as a hydrogen-bond donor (N1-H and N2-H) and acceptor (O6 and N7), creating a cyclic quartet. A central monovalent cation — potassium (K+) being optimal, sodium (Na+) effective, lithium (Li+) poor — co-ordinates the electronegative O6 oxygens of two stacked tetrads, providing electrostatic stabilisation. Two or more stacked G-tetrads constitute a G4, with three or four tetrads being most stable.
The distinction from Watson-Crick base pairing is fundamental. In canonical B-form DNA, guanine pairs with cytosine through three hydrogen bonds involving the Watson-Crick face. In G-tetrads, all four guanines use their Hoogsteen faces, and cytosine plays no structural role at all. This means G4 structures form in single-stranded DNA contexts — telomeric overhangs, transcription bubbles, and replication forks — where one strand is transiently unpaired.
Topology: parallel, antiparallel, and hybrid G4 structures
G4 structures differ in the orientation of their four G-tract strands relative to each other, generating distinct topologies with different loop geometries and pharmacological profiles:
Parallel topology: all four strands run 5-prime to 3-prime in the same direction. The loops connecting G-tracts are all propeller loops, lying laterally. The c-MYC promoter G4 (Pu27 sequence, particularly the Pu22 fragment) adopts a parallel topology in potassium solution, as determined by NMR (Ambrus et al., 2005, Biochemistry). This topology presents wide, flat G-quartet faces that are accessible to small-molecule intercalation.
Antiparallel topology: adjacent strands run in opposite directions, with lateral or diagonal loops. The Oxytricha telomeric d(T4G4)4 sequence adopts an antiparallel basket topology.
Hybrid topology: the human telomeric repeat d(TTAGGG)n forms hybrid-1 and hybrid-2 conformations in K+ solution (Wang and Patel, 1993; Ambrus et al., 2006), with a mixture of parallel and antiparallel strand orientations and propeller, lateral, and diagonal loops. The heterogeneity of telomeric G4 topology has complicated drug design targeting this locus.
G4 structures in telomeres: inhibiting telomerase
Human telomeres consist of tandem TTAGGG repeats extending to a 3-prime single-stranded overhang of 100-200 nucleotides (the G-overhang). Telomerase, the reverse transcriptase enzyme composed of TERT (the catalytic subunit) and TERC (the RNA template), extends this overhang by copying TERC's 5-AAUCCC-3 template. Telomerase is expressed in stem cells, germ cells, and ~85-90% of cancer cells, where it maintains telomere length and enables replicative immortality.
G4 structures formed in the G-overhang directly compete with telomerase binding and extension. Telomerase requires an unstructured 3-prime tail to load onto; a stable G4 at the terminus physically blocks TERT from engaging the substrate. Mergny et al. (2002, EMBO Journal) demonstrated that G4 ligands inhibit telomerase in TRAP assays with IC50 values in the nanomolar range, establishing the G4 stabilisation strategy as a telomerase inhibitor approach. Critically, this would preferentially affect cancer cells (which depend on telomerase for survival) over normal somatic cells (which have already downregulated TERT).
G4 structures in oncogene promoters
The nuclease-hypersensitive element III1 (NHEIII1) of the c-MYC promoter, 85-100 bp upstream of the P1 promoter, contains the Pu27 sequence (and its derivatives Pu22 and the 1245 construct used for drug screening). This G4 controls approximately 80-90% of c-MYC transcriptional activity (Siddiqui-Jain et al., 2002, PNAS). When the G4 forms and is stabilised, it acts as a transcriptional silencer by blocking the recruitment of the transcription factor SP1 and displacing CNBP (cellular nucleic acid binding protein), which normally unfolds the G4 to permit transcription. This represents an intrinsic transcriptional regulatory mechanism that small molecules can modulate by shifting the equilibrium toward the folded G4.
The VEGF (vascular endothelial growth factor) promoter contains a 36-nucleotide G4-forming sequence that suppresses VEGF transcription when stabilised (Sun et al., 2008, Journal of Medicinal Chemistry). Given VEGF's central role in tumour angiogenesis, G4-mediated VEGF suppression is an attractive pharmacological concept. Similarly, the KRAS promoter contains a G4 in a region critical for KRAS gene expression, and BCL2's promoter G4 (the MBR G4 in the major breakpoint region) suppresses this anti-apoptotic oncogene when stabilised. The convergence of anti-proliferative, anti-angiogenic, and pro-apoptotic effects from G4 stabilisation at these four promoters has driven intense ligand development efforts.
G4-resolving helicases: the cellular counterforces
Cells maintain elaborate helicase machinery to unfold G4 structures and prevent transcriptional and replicative stalling. The principal G4 helicases include:
FANCJ (BRIP1/BACH1): a member of the DEAH-box helicase family, FANCJ was the first helicase shown to resolve G4 structures in vitro (London et al., 2008, Nature Structural and Molecular Biology). FANCJ mutations are associated with Fanconi anaemia and increased G4-driven instability at G-rich loci.
RTEL1 (regulator of telomere elongation helicase 1): RTEL1 is critical for telomere replication, displacing T-loops and resolving G4 structures in the telomeric D-loop. Mutations in RTEL1 cause Hoyeraal-Hreidarsson syndrome (a severe form of dyskeratosis congenita) with progressive telomere shortening.
BLM (Bloom syndrome helicase): BLM resolves G4 structures at stalled replication forks genome-wide. BLM deficiency leads to elevated G4-associated DNA breaks and sister chromatid exchanges. BLM physically interacts with RPA (replication protein A) to co-operatively unwind G4s.
DHX36 (RHAU): the most potent G4 helicase, DHX36 shows preferential activity on parallel- topology G4 structures, unfolding them with ATP-dependent translocation. It contains a G4-resolvase motif at its N-terminus that confers G4 specificity beyond its general helicase activity.
G4-stabilising ligands work by out-competing these helicases for G4 binding, or by slowing the kinetics of G4 unfolding sufficiently to create a pharmacological effect. The reference compounds in the field are pyridostatin (PDS), RHPS4 (a pentacyclic acridinium), and telomestatin (a cyclic macrolide from Streptomyces anulatus that is structurally the most telomere-selective). All three inhibit telomerase, induce DNA damage at telomeres and G4-forming oncogene promoters, and show anti-proliferative activity in cancer cell lines.
The phycocyanobilin connection: pi-stacking with G-quartets
This is where the chemistry becomes genuinely interesting, and where the evidence is genuinely absent. Phycocyanobilin (PCB) is the linear tetrapyrrole chromophore of phycocyanin, consisting of four pyrrole rings (rings A, B, C, D) connected by methine bridges, with a fully conjugated pi system extending across all four rings. In its native phycocyanin protein, PCB is covalently bound via ring A to a cysteine residue (Cys84 on the alpha-subunit) and exists in a specific helical conformation. When phycocyanin is digested in the gastrointestinal tract, PCB is released and partially absorbed — its bioavailability and tissue distribution are not well characterised beyond the observation that it is detectable in plasma and urine after spirulina consumption.
G-quartet planes are aromatic systems with a molecular area of approximately 450 square angstroms. The best G4 ligands — telomestatin, PDS, BRACO-19, RHPS4 — are large, flat, aromatic molecules that maximise pi-stacking surface area with the terminal G-quartet face. A linear tetrapyrrole like PCB has a conjugated pi system that, when extended, spans roughly 1.5 x 3.0 nm — considerably larger than most synthetic G4 ligands. In principle, this geometry could permit extensive pi-stacking contact with G-quartet planes.
However, several obstacles complicate this hypothesis. First, PCB is a flexible molecule that adopts helical conformations in solution, reducing its effective planarity and pi-stacking capacity relative to rigid aromatic systems. Second, the intracellular free concentration of PCB is unknown and likely low. Third, no in vitro G4-binding assay with PCB (circular dichroism melting, FRET-based thermal stabilisation, or fluorescence intercalation displacement) has been published. The hypothesis that PCB stabilises G4 structures is chemically plausible but entirely untested and should not be stated as fact.
Spirulina's documented c-MYC suppression: is G4 involvement possible?
Multiple studies have documented that spirulina extract and phycocyanin reduce c-MYC protein expression in cancer cell lines, including hepatocellular carcinoma (Zheng et al., 2013), MCF-7 breast cancer cells (Li et al., 2016), and colon cancer models. The mechanisms invoked in these papers include NF-kappaB suppression (which drives MYC transcription downstream of inflammatory signalling), AMPK activation (which suppresses Wnt/beta-catenin, a major MYC activator), and Nrf2-mediated oxidative stress reduction (which reduces ROS-driven MYC transcription). These are well-grounded mechanistic explanations that require no G4 involvement.
Nevertheless, the correspondence is worth noting: spirulina's anti-proliferative effects and c-MYC downregulation align with the predicted consequences of c-MYC G4 stabilisation at the NHEIII1 promoter element. If PCB were to stabilise the Pu27 G4, it would reduce CNBP- and SP1-mediated MYC transcription by a mechanism entirely distinct from NF-kappaB or AMPK pathways, potentially contributing additively. This is a testable hypothesis that would require G4 thermal stabilisation assays, reporter assays with NHEIII1-luciferase constructs, and ChIP-seq for SP1/CNBP occupancy after PCB treatment. None of these experiments have been published.
Broader cancer biology context
G4-stabilising drugs are in clinical and pre-clinical development. CX-5461 (a RNA Pol I inhibitor that also stabilises G4 structures) has been in Phase I trials for BRCA1/2-deficient haematological malignancies, exploiting synthetic lethality between G4 stabilisation and homologous recombination deficiency. The rationale: HR-deficient cells cannot repair G4- associated DNA breaks caused by stabilising ligands. Spirulina's micronutrient content (iron, zinc, copper, manganese) is relevant here too — these metals are cofactors for the topoisomerase II alpha that resolves G4-associated supercoiling, but their plasma concentrations from dietary spirulina supplementation are unlikely to reach pharmacological relevance for G4 biology.
Summary
G-quadruplex structures at telomeres and oncogene promoters (c-MYC, VEGF, KRAS, BCL2) are established regulatory elements whose stabilisation suppresses telomerase activity and oncogene transcription. The helicase counterforces (FANCJ, RTEL1, BLM, DHX36) maintain G4 resolution during normal DNA metabolism. The pharmacological G4 stabilisation field has produced compelling pre-clinical results. Phycocyanobilin's conjugated tetrapyrrole pi-system is chemically suited for G4 stacking interactions, and spirulina's documented c-MYC suppression is consistent with G4-mediated transcriptional repression at the NHEIII1 element — but consistent with is not the same as caused by. Dedicated biochemical studies are needed before any causal claim can be made.